Local view for "https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/457"
| Predicate | Value (sorted: none) |
|---|---|
| rdf:type | |
| rdf:type | |
| rdfs:label |
"evidence_1749"
|
| ?:Evidence_type | |
| ?:Evidence_enzyme_system | |
| ?:Evidence_object_dose | |
| ?:Evidence_precip_dose | |
| ?:Evidence_value | |
| dc:creator | |
| dc:date |
"10/19/2007 16:34:37"
|
| ?:content |
""
When a single oral 0.25 mg dose of triazolam was coadministered with nefazodone (200 mg BID) at steady state, triazolam half-life and AUC increased 4-fold and peak concentrations increased 1.7-fold. *Nefazodone plasma concentrations were unaffected by triazolam.*""
|
| rdfs:seeAlso |
All properties reside in the graph file:///home/swish/src/ClioPatria/guidelines/dikb.ttl
The resource appears as object in one triple:
{ triazolam_increases_auc_nefazodone, <http://purl.org/swan/1.2/swan-commons#citesAsRefutingEvidence>, evidence_1749 }